Listed

Xenon Pharmaceuticals Inc.

XENENasdaqCIK 1582313HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$123.2m, Q2 FY2026
Net income−$110.7m, Q2 FY2026
Xenon Pharmaceuticals Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reported0.0Revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure7.5Revenue, Q1 FY2025, three months to 2025-03-31$7.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Research and development$m42.9Research and development, Q3 FY2023, three months to 2023-09-30$42.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure41.1Research and development, Q4 FY2023, three months to 2023-12-31$41.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure44.3Research and development, Q1 FY2024, three months to 2024-03-31$44.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure49.7Research and development, Q2 FY2024, three months to 2024-06-30$49.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure57.0Research and development, Q3 FY2024, three months to 2024-09-30$57.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure59.5Research and development, Q4 FY2024, three months to 2024-12-31$59.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure61.2Research and development, Q1 FY2025, three months to 2025-03-31$61.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure75.0Research and development, Q2 FY2025, three months to 2025-06-30$75.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure77.1Research and development, Q3 FY2025, three months to 2025-09-30$77.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure87.7Research and development, Q4 FY2025, three months to 2025-12-31$87.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure88.5Research and development, Q1 FY2026, three months to 2026-03-31$88.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure99.2Research and development, Q2 FY2026, three months to 2026-06-30$99.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Operating income$m(55.7)Operating income, Q3 FY2023, three months to 2023-09-30−$55.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure(53.7)Operating income, Q4 FY2023, three months to 2023-12-31−$53.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(59.0)Operating income, Q1 FY2024, three months to 2024-03-31−$59.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure(69.1)Operating income, Q2 FY2024, three months to 2024-06-30−$69.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure(73.7)Operating income, Q3 FY2024, three months to 2024-09-30−$73.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure(77.5)Operating income, Q4 FY2024, three months to 2024-12-31−$77.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(72.7)Operating income, Q1 FY2025, three months to 2025-03-31−$72.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(94.2)Operating income, Q2 FY2025, three months to 2025-06-30−$94.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure(96.3)Operating income, Q3 FY2025, three months to 2025-09-30−$96.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure(110)Operating income, Q4 FY2025, three months to 2025-12-31−$109.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(112)Operating income, Q1 FY2026, three months to 2026-03-31−$112.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(123)Operating income, Q2 FY2026, three months to 2026-06-30−$123.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m(0.2)Income tax, Q3 FY2023, three months to 2023-09-30−$157.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure(0.2)Income tax, Q4 FY2023, three months to 2023-12-31−$205.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure0.4Income tax, Q1 FY2024, three months to 2024-03-31$412.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure(0.3)Income tax, Q2 FY2024, three months to 2024-06-30−$333.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure(0.3)Income tax, Q3 FY2024, three months to 2024-09-30−$320.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure(3.8)Income tax, Q4 FY2024, three months to 2024-12-31−$3.8m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure0.4Income tax, Q1 FY2025, three months to 2025-03-31$427.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(0.6)Income tax, Q2 FY2025, three months to 2025-06-30−$626.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure0.7Income tax, Q3 FY2025, three months to 2025-09-30$677.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure0.5Income tax, Q4 FY2025, three months to 2025-12-31$538.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(2.6)Income tax, Q1 FY2026, three months to 2026-03-31−$2.6m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(0.6)Income tax, Q2 FY2026, three months to 2026-06-30−$585.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Net income$m(48.5)Net income, Q3 FY2023, three months to 2023-09-30−$48.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure(44.7)Net income, Q4 FY2023, three months to 2023-12-31−$44.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(47.9)Net income, Q1 FY2024, three months to 2024-03-31−$47.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure(57.9)Net income, Q2 FY2024, three months to 2024-06-30−$57.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure(62.8)Net income, Q3 FY2024, three months to 2024-09-30−$62.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure(65.7)Net income, Q4 FY2024, three months to 2024-12-31−$65.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(65.0)Net income, Q1 FY2025, three months to 2025-03-31−$65.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure(84.7)Net income, Q2 FY2025, three months to 2025-06-30−$84.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure(90.9)Net income, Q3 FY2025, three months to 2025-09-30−$90.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure(105)Net income, Q4 FY2025, three months to 2025-12-31−$105.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(102)Net income, Q1 FY2026, three months to 2026-03-31−$102.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure(111)Net income, Q2 FY2026, three months to 2026-06-30−$110.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Diluted EPS$ per share(0.73)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figurenot reported(0.62)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure(0.75)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure(0.81)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figurenot reported(0.83)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(1.07)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure(1.15)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figurenot reported(1.17)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(1.11)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Basic EPS$ per share(0.73)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.73 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figurenot reported(0.62)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure(0.75)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure(0.81)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.81 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figurenot reported(0.83)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.83 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(1.07)Basic EPS, Q2 FY2025, three months to 2025-06-30−$1.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure(1.15)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figurenot reported(1.17)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(1.11)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure

Balance sheet

Cash and equivalents$119.5m, Q2 FY2026
Shareholders' equity$1.24bn, Q2 FY2026
Xenon Pharmaceuticals Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m99.6Cash and equivalents, Q3 FY2023, at 2023-09-30$99.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-08, accession 0000950170-23-061200.Report this figure149Cash and equivalents, FY2023, at 2023-12-31$148.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0000950170-25-029149.Report this figure58.9Cash and equivalents, Q1 FY2024, at 2024-03-31$58.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0000950170-24-057139.Report this figure137Cash and equivalents, Q2 FY2024, at 2024-06-30$136.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0000950170-24-094109.Report this figure87.6Cash and equivalents, Q3 FY2024, at 2024-09-30$87.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure143Cash and equivalents, FY2024, at 2024-12-31$142.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-076650.Report this figure117Cash and equivalents, Q1 FY2025, at 2025-03-31$116.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure135Cash and equivalents, Q2 FY2025, at 2025-06-30$135.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure105Cash and equivalents, Q3 FY2025, at 2025-09-30$104.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure199Cash and equivalents, FY2025, at 2025-12-31$199.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure546Cash and equivalents, Q1 FY2026, at 2026-03-31$545.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure120Cash and equivalents, Q2 FY2026, at 2026-06-30$119.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Current assets$m531Current assets, Q3 FY2023, at 2023-09-30$531.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-08, accession 0000950170-23-061200.Report this figure645Current assets, FY2023, at 2023-12-31$645.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0000950170-25-029149.Report this figure707Current assets, Q1 FY2024, at 2024-03-31$707.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-057139.Report this figure728Current assets, Q2 FY2024, at 2024-06-30$728.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094109.Report this figure660Current assets, Q3 FY2024, at 2024-09-30$659.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure635Current assets, FY2024, at 2024-12-31$635.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076650.Report this figure566Current assets, Q1 FY2025, at 2025-03-31$565.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure500Current assets, Q2 FY2025, at 2025-06-30$500.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure480Current assets, Q3 FY2025, at 2025-09-30$480.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure561Current assets, FY2025, at 2025-12-31$560.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure1,107Current assets, Q1 FY2026, at 2026-03-31$1.11bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure946Current assets, Q2 FY2026, at 2026-06-30$945.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Total assets$m671Total assets, Q3 FY2023, at 2023-09-30$671.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-08, accession 0000950170-23-061200.Report this figure965Total assets, FY2023, at 2023-12-31$964.8m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0000950170-25-029149.Report this figure919Total assets, Q1 FY2024, at 2024-03-31$919.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0000950170-24-057139.Report this figure884Total assets, Q2 FY2024, at 2024-06-30$884.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0000950170-24-094109.Report this figure836Total assets, Q3 FY2024, at 2024-09-30$835.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure798Total assets, FY2024, at 2024-12-31$798.1m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001193125-26-076650.Report this figure743Total assets, Q1 FY2025, at 2025-03-31$743.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure674Total assets, Q2 FY2025, at 2025-06-30$674.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure608Total assets, Q3 FY2025, at 2025-09-30$607.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure633Total assets, FY2025, at 2025-12-31$633.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure1,387Total assets, Q1 FY2026, at 2026-03-31$1.39bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure1,296Total assets, Q2 FY2026, at 2026-06-30$1.30bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Current liabilities$m24.7Current liabilities, Q3 FY2023, at 2023-09-30$24.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-08, accession 0000950170-23-061200.Report this figure27.3Current liabilities, FY2023, at 2023-12-31$27.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0000950170-25-029149.Report this figure22.2Current liabilities, Q1 FY2024, at 2024-03-31$22.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-057139.Report this figure31.3Current liabilities, Q2 FY2024, at 2024-06-30$31.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094109.Report this figure29.7Current liabilities, Q3 FY2024, at 2024-09-30$29.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure35.6Current liabilities, FY2024, at 2024-12-31$35.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076650.Report this figure32.0Current liabilities, Q1 FY2025, at 2025-03-31$32.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure33.0Current liabilities, Q2 FY2025, at 2025-06-30$33.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure38.3Current liabilities, Q3 FY2025, at 2025-09-30$38.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure41.8Current liabilities, FY2025, at 2025-12-31$41.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure39.8Current liabilities, Q1 FY2026, at 2026-03-31$39.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure45.0Current liabilities, Q2 FY2026, at 2026-06-30$45.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Total liabilities$m34.5Total liabilities, Q3 FY2023, at 2023-09-30$34.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-08, accession 0000950170-23-061200.Report this figure36.9Total liabilities, FY2023, at 2023-12-31$36.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0000950170-25-029149.Report this figure31.3Total liabilities, Q1 FY2024, at 2024-03-31$31.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0000950170-24-057139.Report this figure40.0Total liabilities, Q2 FY2024, at 2024-06-30$40.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0000950170-24-094109.Report this figure38.1Total liabilities, Q3 FY2024, at 2024-09-30$38.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure43.2Total liabilities, FY2024, at 2024-12-31$43.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001193125-26-076650.Report this figure39.3Total liabilities, Q1 FY2025, at 2025-03-31$39.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure40.3Total liabilities, Q2 FY2025, at 2025-06-30$40.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure48.3Total liabilities, Q3 FY2025, at 2025-09-30$48.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure51.4Total liabilities, FY2025, at 2025-12-31$51.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure49.0Total liabilities, Q1 FY2026, at 2026-03-31$49.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure53.4Total liabilities, Q2 FY2026, at 2026-06-30$53.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m637Shareholders' equity, Q3 FY2023, at 2023-09-30$636.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure928Shareholders' equity, FY2023, at 2023-12-31$927.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001193125-26-076650.Report this figure888Shareholders' equity, Q1 FY2024, at 2024-03-31$887.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure844Shareholders' equity, Q2 FY2024, at 2024-06-30$844.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure798Shareholders' equity, Q3 FY2024, at 2024-09-30$797.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure755Shareholders' equity, FY2024, at 2024-12-31$754.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure704Shareholders' equity, Q1 FY2025, at 2025-03-31$704.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure634Shareholders' equity, Q2 FY2025, at 2025-06-30$634.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure560Shareholders' equity, Q3 FY2025, at 2025-09-30$559.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure582Shareholders' equity, FY2025, at 2025-12-31$581.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure1,338Shareholders' equity, Q1 FY2026, at 2026-03-31$1.34bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure1,242Shareholders' equity, Q2 FY2026, at 2026-06-30$1.24bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure

Cash flow

Operating cash flow−$95.4m, Q2 FY2026
Capital expenditure$275.0k, Q2 FY2026
Xenon Pharmaceuticals Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(48.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$48.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0000950170-24-125547. Derived: 9-month figure less the 6-month figure.Report this figure(35.4)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$35.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(46.2)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$46.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure(31.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$31.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0000950170-25-106599. Derived: 6-month figure less the 3-month figure.Report this figure(49.7)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$49.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001193125-25-262646. Derived: 9-month figure less the 6-month figure.Report this figure(54.4)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$54.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(61.7)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$61.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(64.2)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$64.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338244. Derived: 6-month figure less the 3-month figure.Report this figure(71.8)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$71.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001193125-25-262646. Derived: 9-month figure less the 6-month figure.Report this figure(81.5)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$81.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure(88.9)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$88.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure(95.4)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$95.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338244. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m1.2Capital expenditure, Q3 FY2023, three months to 2023-09-30$1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0000950170-24-125547. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2023, three months to 2023-12-31$78.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$188.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure1.5Capital expenditure, Q2 FY2024, three months to 2024-06-30$1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0000950170-25-106599. Derived: 6-month figure less the 3-month figure.Report this figure0.6Capital expenditure, Q3 FY2024, three months to 2024-09-30$590.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0001193125-25-262646. Derived: 9-month figure less the 6-month figure.Report this figure0.8Capital expenditure, Q4 FY2024, three months to 2024-12-31$783.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$43.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$157.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338244. Derived: 6-month figure less the 3-month figure.Report this figure0.3Capital expenditure, Q3 FY2025, three months to 2025-09-30$281.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0001193125-25-262646. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2025, three months to 2025-12-31$318.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076650. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$133.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure0.3Capital expenditure, Q2 FY2026, three months to 2026-06-30$275.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338244. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)99.61m, Q2 FY2026
Xenon Pharmaceuticals Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares65.5Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3065,465,069 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-08, accession 0000950170-23-061200.Report this figure65.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3165,724,681 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0000950170-24-057139.Report this figure65.9Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3065,861,138 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0000950170-24-094109.Report this figure66.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3066,002,163 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0000950170-24-125547.Report this figure77.6Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3177,594,599 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0000950170-25-069342.Report this figure77.7Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3077,671,128 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0000950170-25-106599.Report this figure77.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3077,926,205 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure78.7Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3178,687,503 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure79.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3078,953,445 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure79.2Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3079,247,976 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-03, accession 0001193125-25-262646.Report this figure87.3Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3187,345,717 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-212153.Report this figure99.6Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3099,609,804 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure

Shares outstanding: 96.84mShares outstanding, period not labelled, at 2026-08-0396,840,432 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338244.Report this figure at Aug 3, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. Listed shows no prices and gives no investment advice.